Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VGLCR
- Development stage
- Preclinical
- Lead developer
- Novita Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VGLCR is an experimental oral nutraceutical combination formulation designed to counteract the early degenerative changes associated with glaucoma. The composition includes vitamin D3, gastrodin (the active ingredient of *Gastrodia elata*), lycopene, vitamin C, and blackcurrant extract, formulated using the patented FM-LipoMatrix® technology to enhance delivery. VGLCR acts as a neuroprotective agent for retinal ganglion cells (RGCs) by counteracting reactive oxygen species (ROS) production, inhibiting apoptotic cycles (via p53, Bax, and Annexin V modulation), and regulating key intracellular signaling pathways such as p38 MAPK, JNK, and ERK. Research conducted at the University of Eastern Piedmont has demonstrated its potential to prevent and restore retinal damage in both in vitro mouse RGC models and ex vivo bovine eyecup preparations.
- Other names
- vitamin D3 + gastrodin + lycopene + vitamin C + blackcurrant extract
02
Targets
BAX (Apoptosis regulator BAX)TP53 (Cellular Tumor Antigen p53 R175H)OPA1 (OPA1 mitochondrial dynamin-like GTPase)MAPK3 (Mitogen-activated protein kinase 1)NOS2 (Nitric Oxide Synthase 2)MMP9 (Matrix metalloproteinase-9)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)JNK (Mitogen-activated protein kinase kinase kinase family)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on VGLCR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VGLCR.